Development of Serine Protease Inhibitors Displaying a Multicentered Short (<2.3 Å) Hydrogen Bond Binding Mode:  Inhibitors of Urokinase-Type Plasminogen Activator and Factor Xa

Novel scaffolds that bind to serine proteases through a unique network of short hydrogen bonds to the catalytic Ser195 have been developed. The resulting potent serine protease inhibitors were designed from lead molecule 2-(2-hydroxyphenyl)1H-benzoimidazole-5-carboxamidine, 6b, which is known to dis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2001-08, Vol.44 (17), p.2753-2771
Hauptverfasser: Verner, Erik, Katz, Bradley A, Spencer, Jeffrey R, Allen, Darin, Hataye, Jason, Hruzewicz, Witold, Hui, Hon C, Kolesnikov, Aleksandr, Li, Yong, Luong, Christine, Martelli, Arnold, Radika, Kesavan, Rai, Roopa, She, Miles, Shrader, William, Sprengeler, Paul A, Trapp, Sean, Wang, Jing, Young, Wendy B, Mackman, Richard L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Novel scaffolds that bind to serine proteases through a unique network of short hydrogen bonds to the catalytic Ser195 have been developed. The resulting potent serine protease inhibitors were designed from lead molecule 2-(2-hydroxyphenyl)1H-benzoimidazole-5-carboxamidine, 6b, which is known to display several modes of binding. For instance, 6b can recruit zinc and bind in a manner similar to that reported by bis(5-amidino-2-benzimidazolyl)methane (BABIM) (Nature 1998, 391, 608−612). Alternatively, 6b can bind in the absence of zinc through a multicentered network of short (
ISSN:0022-2623
1520-4804
DOI:10.1021/jm0100638